At 2014 San Antonio Breast Cancer Symposium three new Myriad studies highlighted
Myriad Genetics, Inc. (NASDAQ: MYGN) has announced results from a new study that demonstrated the ability of the myRisk™ Hereditary Cancer test to detect 105 percent more mutations in cancer...